Phase 3 Heart Disease Trial, Recruiting (NCT06694727)

Phase 3 Heart Disease Trial, Recruiting NCT06694727 Sponsor: Tor Biering-Sørensen Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06694727 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older.
People who have a heart failure diagnosis recorded as a primary hospital discharge diagnosis in the Danish National Patient Registry, and who have had at least one dispensed prescription for two specific types of heart medications (a renin-angiotensin-system inhibitor and a beta-blocker) within 120 days of that heart failure diagnosis being recorded.
People who have signed and dated an informed consent form agreeing to take part in the trial.

Who may not be able to join:

People who are currently using a type of blood-thinning medication known as a vitamin K-antagonist (such as warfarin).
People who have a cancer diagnosis recorded in the Danish National Patient Registry within the last 5 years, with the exception of certain skin cancers (specifically squamous cell carcinoma or basal cell carcinoma of the skin) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tor Biering-Sørensen, MD, MPH, MSc, PhD, Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Phone: +4542451250

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06694727

Sponsor: Tor Biering-Sørensen

Phase: Phase 3

Status: Recruiting

Condition: Heart Disease

Trial contact: +4542451250

More information: https://clinicaltrials.gov/study/NCT06694727

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older.
People who have a heart failure diagnosis recorded as a primary hospital discharge diagnosis in the Danish National Patient Registry, and who have had at least one dispensed prescription for two specific types of heart medications (a renin-angiotensin-system inhibitor and a beta-blocker) within 120 days of that heart failure diagnosis being recorded.
People who have signed and dated an informed consent form agreeing to take part in the trial.

Who may not be able to join:

People who are currently using a type of blood-thinning medication known as a vitamin K-antagonist (such as warfarin).
People who have a cancer diagnosis recorded in the Danish National Patient Registry within the last 5 years, with the exception of certain skin cancers (specifically squamous cell carcinoma or basal cell carcinoma of the skin) (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Tor Biering-Sørensen

Registry

ClinicalTrials.gov

Start date

30 September 2025

Est. completion

1 December 2028

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Time to the first occurrence of hospitalization for heart failure or cardiovascular death

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov